This strategy may provide an indispensable technology for the evaluation of NPC1 and other lysosomal storage diseases in an MV context, i.e., that involving rapid urine screening at patient points of contact (for example, at dedicated health clinics and services, clinical practitioner practices, etc.). Here, NPC1 is linked to lysosomal storage disease.